For Doctors in a Hurry
- Researchers investigated the role of sirtuin 5 in cardiac fibroblast activation and the development of cardiac fibrosis.
- The study analyzed cardiac tissue from humans and mice, utilizing fibroblast-specific genetic knockout and overexpression models in mice.
- SIRT5 expression was markedly reduced in heart failure, while its loss exacerbated left ventricular dysfunction and fibrosis.
- The authors concluded that SIRT5 prevents fibrosis by desuccinylating the enzyme PCK2 to maintain normal cellular metabolism.
- Targeting the PCK2 succinylation site may offer a future strategy to mitigate pathological cardiac remodeling and fibrosis.
Cardiac fibrosis remains a central pathological feature of heart failure, characterized by the excessive deposition of extracellular matrix that impairs ventricular compliance and electrical conduction. While traditional management focuses on neurohormonal blockade, the underlying epigenetic and metabolic shifts that drive fibroblast activation are increasingly recognized as critical therapeutic targets [1]. Chronic inflammation and oxidative stress within the myocardial microenvironment further exacerbate this remodeling process, involving the production of reactive species and lipid peroxidation products (the oxidative degradation of lipids) that trigger cellular damage [2, 3, 4]. These pathological changes involve active phenotypic transitions, such as epithelial-mesenchymal transition (a process where cells lose their organized structure to acquire a migratory, collagen-producing phenotype), and metabolic adaptations within resident cell populations [5, 6, 7]. A new study now identifies that SIRT5 (sirtuin 5) expression is significantly downregulated in the cardiac fibroblasts of patients with heart failure, leading to the succinylation of PCK2 (phosphoenolpyruvate carboxykinase 2) at the Lys489 residue, which drives a metabolic shift toward glycolysis and promotes fibrotic activation [8].
SIRT5 Downregulation in Clinical and Experimental Heart Failure
SIRT5 (sirtuin 5) belongs to the sirtuin family of nicotinamide adenine dinucleotide dependent enzymes, which are essential regulators of mitochondrial health and cellular aging. While their role in cardiomyocyte longevity is well documented, their specific influence on the metabolic state of cardiac fibroblasts (the primary cells responsible for extracellular matrix synthesis) has only recently been elucidated. In the healthy myocardium, SIRT5 functions as a desuccinylase (an enzyme that removes succinyl groups from proteins to maintain their proper function), ensuring that metabolic pathways remain balanced during physiological stress. The researchers analyzed SIRT5 expression across clinical and experimental models of myocardial dysfunction to determine its relevance to disease progression. They found that SIRT5 expression was markedly reduced in cardiac fibroblasts from humans with heart failure, a finding that was consistently replicated in animal studies. Specifically, SIRT5 expression was also markedly reduced in cardiac fibroblasts from mice with heart failure, suggesting that the depletion of this enzyme is a conserved pathological feature of ventricular remodeling across species. These observations indicate that the loss of SIRT5 is not merely a byproduct of cellular stress but a consistent marker of the failing heart. Clinical relevance is further underscored by the relationship between enzyme levels and structural damage. The study demonstrated that SIRT5 expression levels showed a negative correlation with the severity of cardiac fibrosis, where lower concentrations of the enzyme were associated with more extensive collagen deposition and myocardial stiffening. This inverse relationship suggests that the downregulation of SIRT5 may serve as a primary driver of fibrotic activation, providing a potential target for therapeutic stabilization of the cardiac fibroblast phenotype.
Impact of Fibroblast-Specific SIRT5 Deletion on Ventricular Function
To investigate the causal role of SIRT5 in myocardial remodeling, the researchers utilized a mouse model involving transverse aortic constriction (a surgical procedure that creates pressure overload by narrowing the aorta, thereby simulating the hemodynamics of clinical aortic stenosis or chronic hypertension). In mice where the Sirt5 gene was specifically deleted within cardiac fibroblasts, the response to this pressure overload was significantly more severe than in control animals. Specifically, the loss of Sirt5 in cardiac fibroblasts exacerbated left ventricular dysfunction, leading to a more pronounced decline in contractile performance. Furthermore, these Sirt5-deficient mice demonstrated exacerbated cardiac hypertrophy, characterized by an abnormal increase in heart muscle mass, and exacerbated cardiac fibrosis following the transverse aortic constriction procedure. These findings indicate that the presence of SIRT5 in fibroblasts is essential for limiting the structural and functional damage caused by chronic mechanical stress. Conversely, the study explored whether increasing the levels of this enzyme could provide a protective effect against the progression of heart failure. The researchers employed a model involving the overexpression of Sirt5 specifically within the cardiac fibroblasts of mice. When these animals were subjected to the same pressure overload conditions, the results were markedly different from the deficiency models. The overexpression of Sirt5 in cardiac fibroblasts significantly attenuated left ventricular dysfunction, hypertrophy, and fibrosis, effectively preserving cardiac geometry and pumping capacity. This contrast between the knockout and overexpression models suggests that SIRT5 activity in fibroblasts serves as a critical endogenous defense mechanism. For the clinician, these data suggest that maintaining or restoring SIRT5 function could potentially stabilize ventricular function and prevent the transition from compensated hypertrophy to overt heart failure.
The Glycolytic Shift and PCK2 Inactivation
The structural remodeling observed in SIRT5-deficient hearts is driven by a fundamental alteration in how fibroblasts process energy. The researchers found that Sirt5 deficiency promoted cardiac fibroblast activation by driving a metabolic shift from oxidative phosphorylation to glycolysis. In a physiological state, quiescent fibroblasts rely on oxidative phosphorylation (the efficient production of adenosine triphosphate within the mitochondria using oxygen). However, the loss of SIRT5 forces these cells to transition to glycolysis (the anaerobic breakdown of glucose for energy). This metabolic reprogramming is a characteristic feature of activated myofibroblasts, providing the biosynthetic precursors necessary for the rapid production of extracellular matrix proteins that characterize cardiac fibrosis. The molecular mechanism for this transition centers on the regulation of phosphoenolpyruvate carboxykinase 2 (PCK2), a key enzyme linking glycolysis and the tricarboxylic acid cycle. SIRT5 normally functions as a desuccinylase, removing succinyl groups from lysine residues to maintain protein function. The study revealed that Sirt5 deficiency increased the succinylation of PCK2 at the Lys489 residue, a post-translational modification involving the addition of a succinyl group to the protein. This specific modification at the Lys489 site is critical because succinylation at Lys489 inhibited PCK2 enzyme activity in cardiac fibroblasts. By suppressing PCK2 activity, the loss of SIRT5 disrupts the metabolic bridge to the tricarboxylic acid cycle, thereby reinforcing the glycolytic shift and sustaining the hyperactivated, pro-fibrotic state of the cardiac fibroblasts.
To confirm that the inhibition of phosphoenolpyruvate carboxykinase 2 (PCK2) was the primary driver of pathological remodeling, the researchers employed a targeted molecular intervention. They introduced a Lys489-to-arginine (K489R) mutation of PCK2, a precise genetic modification designed to prevent succinylation at that specific lysine site by replacing it with an amino acid that cannot be succinylated. In vitro experiments demonstrated that this mutation, which renders the protein immune to the inhibitory effects of succinyl group addition, effectively reversed the metabolic reprogramming in Sirt5-deficient cardiac fibroblasts. By restoring the normal function of PCK2, the cells transitioned away from their pathological reliance on glycolysis and returned to a more oxidative metabolic state. Furthermore, the Pck2 K489R mutation reversed the hyperactivation of cardiac fibroblasts induced by Sirt5 knockout, indicating that the pro-fibrotic phenotype is directly dependent on the succinylation status of this metabolic enzyme. The therapeutic potential of this pathway was further validated through in vivo models of pressure overload. In mice subjected to transverse aortic constriction, the researchers observed that introducing the Pck2 K489R mutation fully rescued the exacerbated cardiac fibrosis observed in Sirt5-deficient mice. This molecular correction did more than just reduce collagen deposition; it also translated to preserved organ function. Specifically, the Pck2 K489R mutation fully rescued the exacerbated cardiac dysfunction observed in Sirt5-deficient mice after transverse aortic constriction, preventing the precipitous decline in ventricular performance typically seen when SIRT5 is absent. These findings establish that SIRT5 protects against cardiac fibrosis by desuccinylating PCK2 at Lys489, preventing metabolic reprogramming and fibroblast activation. By maintaining PCK2 in its desuccinylated, active form, SIRT5 ensures metabolic homeostasis and prevents the transition of quiescent fibroblasts into the hyperactivated myofibroblasts that drive heart failure progression.
References
1. Shi Y, Zhang H, Huang S, et al. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01055-2
2. Pacher P, Beckman JS, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiological Reviews. 2007. doi:10.1152/physrev.00029.2006
3. Guo Q, Jin Y, Chen X, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01757-9
4. Ayala A, Muñoz M, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxidative Medicine and Cellular Longevity. 2014. doi:10.1155/2014/360438
5. Yang J, Antin PB, Berx G, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nature Reviews Molecular Cell Biology. 2020. doi:10.1038/s41580-020-0237-9
6. Chen S, Saeed AFUH, Liu Q, et al. Macrophages in immunoregulation and therapeutics. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01452-1
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation. 2009. doi:10.1172/jci39104
8. Wu M, Tan J, Zhou W, et al. SIRT5 Ameliorates Cardiac Fibrosis via PCK2 Desuccinylation-Mediated Metabolic Reprogramming in Cardiac Fibroblasts.. Circulation. 2026. doi:10.1161/CIRCULATIONAHA.125.077756
